Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). We evaluated the efficacy of the IPI and revised IPI (R-IPI) in patients with DLBCL who were treated with R-CHOP, focusing on extranodal site number (ENS)because extranodal involvement occurs frequently in Koreans. Methods: A total of 126 R-CHOP-treated patients with stage III/IV DLBCL were analyzed. We performed a retrospective analysis of the clinicopathologic factors and verified the predictive power of the standard IPI and RIPI. Various numbers of extranodal sites were analyzed for further stratification, and we set the extranodal sitemodified IPI (E-IPI) as the IPI when the number of extranodal sites was stratified as < 3 vs. ≥ 3. Results: A univariate analysis showed that ENS was associated with complete response (CR, p = 0.04), eventfree survival (EFS, p = 0.01), and overall survival (OS, p < 0.001) when the ENS cut-off was set at ≥ 3. A multivariate analysis revealed that an ENS ≥ 3 remained associated with EFS (p < 0.01; hazard ratio [HR], 2.60;95% confidence interval [CI], 1.29 to 5.26) and OS (p < 0.01; HR, 3.52; 95% CI, 1.68 to 7.35). The IPI was effective for determining prognosis in terms of OS (p = 0.04) but not EFS (p = 0.17). The R-IPI was effective in terms of both variables (p = 0.02 and 0.04, respectively), as was the E-IPI (p = 0.01 and 0.001, respectively). Conclusions: An ENS < 3 vs. ≥ 3, rather than the original < 2 vs. ≥ 2, was the most significant prognostic factor for EFS and OS. All three indices were predictive, but only the E-IPI identified the high-risk group of R-CHOPtreated Korean patients with disseminated DLBCL. (Korean J Intern Med 2010;25:301-308)
Abstract
Background/Aims: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). We evaluated the efficacy of the IPI and revised IPI (R-IPI) in patients with DLBCL who were treated with R-CHOP, focusing on extranodal site number (ENS)because extranodal involvement occurs frequently in Koreans. Methods: A total of 126 R-CHOP-treated patients with stage III/IV DLBCL were analyzed. We performed a retrospective analysis of the clinicopathologic factors and verified the predictive power of the standard IPI and RIPI. Various numbers of extranodal sites were analyzed for further stratification, and we set the extranodal sitemodified IPI (E-IPI) as the IPI when the number of extranodal sites was stratified as < 3 vs. ≥ 3. Results: A univariate analysis showed that ENS was associated with complete response (CR, p = 0.04), eventfree survival (EFS, p = 0.01), and overall survival (OS, p < 0.001) when the ENS cut-off was set at ≥ 3. A multivariate analysis revealed that an ENS ≥ 3 remained associated with EFS (p < 0.01; hazard ratio [HR], 2.60;95% confidence interval [CI], 1.29 to 5.26) and OS (p < 0.01; HR, 3.52; 95% CI, 1.68 to 7.35). The IPI was effective for determining prognosis in terms of OS (p = 0.04) but not EFS (p = 0.17). The R-IPI was effective in terms of both variables (p = 0.02 and 0.04, respectively), as was the E-IPI (p = 0.01 and 0.001, respectively). Conclusions: An ENS < 3 vs. ≥ 3, rather than the original < 2 vs. ≥ 2, was the most significant prognostic factor for EFS and OS. All three indices were predictive, but only the E-IPI identified the high-risk group of R-CHOPtreated Korean patients with disseminated DLBCL. (Korean J Intern Med 2010;25:301-308)
참고문헌 (18)
- Fisher RI, "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma", N Engl J Med, 328, pp.1002~1006 (1993)
- Park YH, "Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients", Ann Hematol, 85, pp.257~262 (2006)
- Pfreundschuh M, "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group", Lancet Oncol, 7, pp.379~391 (2006)
- Feugier P, "Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l’Adulte", J Clin Oncol, 23, pp.4117~4126 (2005)
- Lossos IS, "Prognostic biomarkers in diffuse large B-cell lymphoma", J Clin Oncol, 24, pp.995~1007 (2006)
- Hermans J, "International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades", Blood, 86, pp.1460~1463 (1995)
- Ko YH, "REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features: Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma", Cancer, 83, pp.806~812 (1998)
- Greiner TC, "Non-Hodgkin's lymphoma", Cancer, 75, pp.370~380 (1995)
- Ho FC, "Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period", Int J Cancer, 34, pp.143~148 (1984)
- Hahn JS, "Eight-year experience of malignant lymphoma: survival and prognostic factors", Yonsei Med J, 38, pp.270~284 (1997)
- Kim HT, "Malignant lymphomas in Korea", J Korean Cancer Assoc, 24, pp.92~101 (1992)
- Mounier N, "Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)", Blood, 101, pp.4279~4284 (2003)
- Wilson KS, "CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma", Leuk Lymphoma, 48, pp.1102~1109 (2007)
- Ngo L, "Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab", Leuk Lymphoma, 49, pp.462~469 (2008)
- Sehn LH, "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP", Blood, 109, pp.1857~1861 (2007)
- Ennishi D, "CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy", Ann Oncol, 19, pp.1921~1926 (2008)
- Cheson BD, "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group", J Clin Oncol, 17, pp.1244~ (1999)
- 고옥배, "Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement", The Korean Journal of Internal Medicine, 23(4), pp.182~190 (2008), 대한내과학회